Cited by 175Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice

Boimel, Moran, Grigoriadis, Nikolaos, Lourbopoulos, Athanasios, Haber, Esther, Abramsky, Oded, Rosenmann, Hanna·2010·Experimental Neurology

DOI 10.1016/j.expneurol.2010.05.010

Open this paper in CoChat — free account

Abstract

As an abnormally folded and aggregated protein, tau composed of neurofibrillary tangles (NFTs) in Alzheimer's disease and other tauopathies seems to be a candidate for immunotherapy. Yet, the encephalitogenicity of full-length tau protein, recently reported by us in immunized mice, demands to carefully and selectively target pathological tau and address both efficacy (anti-NFT effect) and safety (free of encephalitis). We immunized NFT mice with NFT-related phosphorylated (phos) tau peptides, using an immunization protocol aimed to predispose a proinflammatory milieu in CNS as a set up to detect biohazard, an approach we used when the neurotoxicity of full-length tau was detected [use of complete Freund adjuvant (CFA) with pertussis toxin (PT)]. A decrease of about 40% in NFT burden in CNS was demonstrated and was accompanied with an increase in microglial burden. Anti-phos-tau antibodies were detected in serum and blood vessels in the CNS, while no encephalitogenicity (free of clinical neurological deficits, of adverse effects on brain inflammatory cells and of axonal damage) was recorded. The level of the lysosomal proteases, cathepsins D and L, was affected in the immunized mice suggesting the possible involvement of the lysosomal system in the decrease of NFTs. The robust anti-NFT effect and the lack of encephalitogenicity in NFT mice immunized with phos-tau peptides, even though CFA with PT was included in vaccine, point to their anti-NFT therapeutic potential.

Integrity signals

Registry

Crossref · 10.1016/j.expneurol.2010.05.010

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
Classification and basic pathology of Alzheimer disease
Duyckaerts, C., Delatour, B., & Potier, M.-C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0532-1 · Cited by 1,031
Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780
Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease
Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., & LaFerla, F. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2868-05.2005 · Cited by 697
Rapamycin alleviates toxicity of different aggregate-prone proteins
Berger, Z., Ravikumar, B., Menzies, F. M., Oroz, L. G., Underwood, B. R., Pangalos, M. N., Schmitt, I., Wullner, U., Evert, B. O., O'Kane, C. J., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddi458 · Cited by 657
Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing
Wang, Y., Martinez-Vicente, M., Krüger, U., Kaushik, S., Wong, E., Mandelkow, E.-M., Cuervo, A. M., & Mandelkow, E. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp367 · Cited by 617

Show all 41 references

Research works printed but not linked: 2

Boimel, 2006, Inflammation in the CNS increases Alzheimer's disease related neurofibrillary tangle burden: a study of experimental autoimmune encephalomyelitis in a transgenic animal model for neurofibrillary tangles, Neurology, 66, 279
Lourbopoulos, 2007, Modified Bielschowsky silver impregnation combined with hematoxylin or cresyl violet counterstaining as a potential tool for the simultaneous study of inflammation and axonal injury in the central nervous system, Aristotle Univer. Med. J., 34, 31

Sorted by citations

Items 101–175 of 175

Prion-Like Propagation of Protein Aggregation and Related Therapeutic Strategies
Kaufman, S. K., & Diamond, M. I. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0196-3 · Cited by 40
Tau and Alzheimer's disease: Past, present and future
Iqbal, K. (2024) · Cytoskeleton · doi:10.1002/cm.21822 · Cited by 35
Immunotherapy for Tauopathies
Gu, J., & Sigurdsson, E. M. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9576-5 · Cited by 36
Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach
Shamir, D. B., Rosenqvist, N., Rasool, S., Pedersen, J. T., & Sigurdsson, E. M. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.01.013 · Cited by 34
Beyond Amyloid
Lane, R. F., Shineman, D. W., Steele, J., Lee, L. H., & Fillit, H. M. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00007-6 · Cited by 35
Prion-like Mechanisms in Alzheimer's Disease
Yin, R., Tan, L., Jiang, T., & Yu, J. (2014) · Current Alzheimer Research · doi:10.2174/156720501108140910121425 · Cited by 33
Tau immunization: a cautionary tale?
Mably, A. J., Kanmert, D., Donald, J. M. M., Liu, W., Caldarone, B. J., Lemere, C. A., O’Nuallain, B., Kosik, K. S., & Walsh, D. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.11.022 · Cited by 32
Innate immunity in Alzheimer’s disease: the relevance of animal models?
Franco-Bocanegra, D., Nicoll, J. A. R., & Boche, D. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1729-4 · Cited by 32
MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice
Davtyan, H., Chen, W. W., Zagorski, K., Davis, J., Petrushina, I., Kazarian, K., Cribbs, D. H., Agadjanyan, M. G., Blurton-Jones, M., & Ghochikyan, A. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.020 · Cited by 30
Emerging Promise of Immunotherapy for Alzheimer’s Disease: A New Hope for the Development of Alzheimer’s Vaccine
Kabir, M. T., Uddin, M. S., Mathew, B., Das, P. K., Perveen, A., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200422105156 · Cited by 32
Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein
Smith, L. M., Coffey, M. P., Klaver, A. C., & Loeffler, D. A. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.04.034 · Cited by 30
Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology
Joly‐Amado, A., Davtyan, H., Serraneau, K. S., Jules, P., Zitnyar, A., Pressman, E., Zagorski, K., Antonyan, T., Hovakimyan, A., Paek, H., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104636 · Cited by 30
Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs
Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27
Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer’s Disease
Bartos, A., Fialová, L., & Švarcová, J. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180039 · Cited by 25
Recent advances in tau-directed immunotherapy against Alzheimer’s disease: an overview of pre-clinical and clinical development
Ng, P. Y., Chang, I. S., Koh, R. Y., & Chye, S. M. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00591-6 · Cited by 25
Tau Immunotherapy and Imaging
Sigurdsson, E. M. (2013) · Neurodegenerative Diseases · doi:10.1159/000354491 · Cited by 23
Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser422 containing epitope on pathological tau
van Ameijde, J., Crespo, R., Janson, R., Juraszek, J., Siregar, B., Verveen, H., Sprengers, I., Nahar, T., Hoozemans, J. J. M., Steinbacher, S., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0562-9 · Cited by 21
Harnessing the Immune System for Treatment and Detection of Tau Pathology
Congdon, E. E., Krishnaswamy, S., & Sigurdsson, E. M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132435 · Cited by 20
Clinical Trials: Past, Current, and Future for Atypical Parkinsonian Syndromes
Boxer, A. L., & Tsai, R. M. (2014) · Seminars in Neurology · doi:10.1055/s-0034-1381739 · Cited by 19
NPAS4 Facilitates the Autophagic Clearance of Endogenous Tau in Rat Cortical Neurons
Fan, W., Long, Y., Lai, Y., Wang, X., Chen, G., & Zhu, B. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0692-5 · Cited by 18
Perspectives in Molecular Imaging Using Staging Biomarkers and Immunotherapies in Alzheimer’s Disease
Leclerc, B., & Abulrob, A. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/589308 · Cited by 18
Pathogenic Tau Protein Species: Promising Therapeutic Targets for Ocular Neurodegenerative Diseases
Mishan, M. A., Kanavi, M. R., Shahpasand, K., & Ahmadieh, H. (2019) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v14i4.5459 · Cited by 18
Clearing the way for tau immunotherapy in Alzheimer's disease
Herrmann, A. G., & Spires‐Jones, T. L. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12845 · Cited by 18
From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimers Disease
Alarcón‐Espósito, J., Mallea, M., & Rodríguez-Lavado, J. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200914155951 · Cited by 19
Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer’s Disease Like Tau Aggregation
Richter, M., Mewes, A., Fritsch, M., Krügel, U., Hoffmann, R., & Singer, D. L. (2014) · Vaccines · doi:10.3390/vaccines2030601 · Cited by 17
Recent advances in the development of immunotherapies for tauopathies
Ubhi, K. K., & Masliah, E. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.10.007 · Cited by 16
Should development of Alzheimer¿s disease-specific intravenous immunoglobulin be considered?
Loeffler, D. A. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0198-z · Cited by 15
Recent Trends in Active and Passive Immunotherapies of Alzheimer’s Disease
Alshamrani, M. (2023) · Antibodies · doi:10.3390/antib12020041 · Cited by 17
Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?
Kayed, R., Castillo‐Carranza, D. L., & Guerrero‐Munoz, M. J. (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s40131 · Cited by 16
Genetic factors related to the immune system in subjects at risk of developing Alzheimer's disease
Prendecki, M., Kowalska, M., Łagan-Jędrzejczyk, U., Piekut, T., Krokos, A., Kozubski, W. P., & Dorszewska, J. (2020) · Journal of Integrative Neuroscience · doi:10.31083/j.jin.2020.02.110 · Cited by 11
Therapeutic Targets in Alzheimer's Disease and Related Tauopathies
Corbo, C. P., & Alonso, A. D. C. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385506-0.00002-8 · Cited by 13
Effects of Tau Domain-Specific Antibodies and Intravenous Immunoglobulin on Tau Aggregation and Aggregate Degradation
Esteves-Villanueva, J. O., Trzeciakiewicz, H., Loeffler, D. A., & Martić, S. (2014) · Biochemistry · doi:10.1021/bi501272x · Cited by 12
Plant-based vaccines for Alzheimer's disease: an overview
Rosales‐Mendoza, S., Rubio‐Infante, N., Zarazúa, S., Govea‐Alonso, D. O., Martel‐Gallegos, G., & Moreno‐Fierros, L. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.874948 · Cited by 11
Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques
Benhamron, S., Rozenstein‐Tsalkovich, L., Nitzan, K., Abramsky, O., & Rosenmann, H. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.02.004 · Cited by 11
Self-citation
Selective neutralization of APP-C99 with monoclonal antibodies reduces the production of Alzheimer's Aβ peptides
Houacine, J., Bolmont, T., Aeschbach, L., Oulad‐Abdelghani, M., & Fraering, P. C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.033 · Cited by 10
Active immunotherapy against pathogenic Cis pT231-tau suppresses neurodegeneration in traumatic brain injury mouse models
Alipour, M., Tebianian, M., Tofigh, N., Taheri, R. S., Mousavi, S. A., Naseri, A., Ahmadi, A., Munawar, N., & Shahpasand, K. (2022) · Neuropeptides · doi:10.1016/j.npep.2022.102285 · Cited by 9
ENU Mutagenesis Screen to Establish Motor Phenotypes in Wild‐Type Mice and Modifiers of a Pre‐Existing Motor Phenotype in Tau Mutant Mice
Liu, X., Dobbie, M. S., Tunningley, R., Whittle, B., Zhang, Y., Ittner, L. M., & Götz, J. (2011) · BioMed Research International · doi:10.1155/2011/130947 · Cited by 11
Development of an anti-tauopathy mucosal vaccine specifically targeting pathologic conformers
Tan, W., Thiruppathi, J., Hong, S. H., Puth, S., Pheng, S., Mun, B.-R., Choi, W., Lee, K., Park, H., Nguyen, D. T., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00904-1 · Cited by 10
Targeting tau in Alzheimer’s Disease: rationale, approach and challenges
Aslanyan, A., Foiani, M. S., Giovannucci, T. A., McDade, E., Duff, K., Mummery, C. J., Schöll, M., Wildsmith, K. R., & Paterson, R. W. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00925-5 · Cited by 10
Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study
Klaver, A. C., Coffey, M. P., Bennett, D. A., & Loeffler, D. A. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0100-x · Cited by 9
Alzheimers Disease: Review of Emerging Treatment Role for Intravenous Immunoglobulins
Kayed, R., Jackson, G. R., Estes, D. M., & Barrett, A. D. T. (2011) · Journal of Central Nervous System Disease · doi:10.4137/jcnsd.s5018 · Cited by 9
Therapeutic applications of antibodies in non-infectious neurodegenerative diseases
Krishnamurthy, P., & Sigurdsson, E. M. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.020 · Cited by 8
Tau-based therapies for Alzheimer’s disease: Promising novel neuroprotective approaches
Sayas, C. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814037-6.00005-7 · Cited by 9
Effects of antibodies to phosphorylated and non-phosphorylated tau on in vitro tau phosphorylation at Serine-199: Preliminary report
Loeffler, D. A., Smith, L. M., Klaver, A. C., & Martić, S. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2015.04.010 · Cited by 7
Intravenous Injection of PHF-Tau Proteins From Alzheimer Brain Exacerbates Neuroinflammation, Amyloid Beta, and Tau Pathologies in 5XFAD Transgenic Mice
Houben, S., de Fisenne, M.-A., Ando, K., Dries, V. V., Poncelet, L., Yilmaz, Z., Mansour, S., Decker, R. D., Brion, J., & Leroy, K. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00106 · Cited by 9
Ovariectomy and High Fat-Sugar-Salt Diet Induced Alzheimer's Disease/Vascular Dementia Features in Mice
Sweetat, S., Shabat, M. B., Theotokis, P., Suissa, N., Karafoulidou, E., Touloumi, O., Abu‐Fanne, R., Abramsky, O., Wolf, G., Saada, A., et al. (2024) · Aging and Disease · doi:10.14336/ad.2024.03110 · Cited by 6
Self-citation
Clinical Biomarkers and Novel Drug Targets to Cut Gordian Knots of Alzheimer's Disease
Mir, R. H., Masoodi, M. H., Shah, A. J., Mohi-ud-din, R., Sabreen, S., Wani, T. U., Jan, R., Javed, M. N., & Mir, P. A. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220903095837 · Cited by 6
All-Trans Retinoic Acid-Induced Cell Surface Heat Shock Protein 90 Mediates Tau Protein Internalization and Degradation in Human Microglia
Nguyen, N. L., Hoang, T. X., & Kim, J. Y. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04295-1 · Cited by 6
Potential Therapeutic Strategies to Prevent the Progression of Alzheimer to Disease States
Aso, E., & Ferrer, I. (2013) · InTech eBooks · doi:10.5772/54783 · Cited by 5
Tau Immunotherapy
Sigurdsson, E. M. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_8 · Cited by 3
Pin1 Protects Against Alzheimer's Disease: One Goal, Multiple Mechanisms
Pastorino, L., Kondo, A., Zhen, X., & Lu, K. P. (2013) · InTech eBooks · doi:10.5772/55085 · Cited by 2
Frontotemporal lobar degeneration
Kim, B., Viera-Ortiz, A., Phan, J. M., Irwin, D. J., & Lee, E. B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00041-1 · Cited by 3
Preclinical models of Alzheimer’s disease for identification and preclinical validation of therapeutic targets: from fine-tuning strategies for validated targets to new venues for therapy
Vasconcelos, B., Bird, M., Stancu, I., Terwel, D., & Dewachter, I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805120-7.00006-3 · Cited by 2
Intracerebroventricular phospho-tau immunotherapy alleviates cortical phospho-tau burden and motor phenotype in a neuron-specific P301S tauopathy mouse
Kemppainen, S., Aramburu-Núñez, M., Koivisto, H., Posado-Fernández, A., Felix-Garcia, M. R., Nurminen, K., Häkli, S., Abellí‐Deulofeu, E., Kaisto, M., Custodia, A., et al. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115315 · Cited by 1
Tau Oligomers as Potential Drug Target for Alzheimer Disease (AD) Treatment
Kayed, R. (2011) · InTech eBooks · doi:10.5772/16682 · Cited by 1
Conformation-Dependent Antibodies as Tools for Characterization of Amyloid Protein Aggregates
Wu, J., & Breydo, L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394431-3.00008-0 · Cited by 1
Pharmacologictherapy for FTD and related disorders
Tsai, R. M., & Boxer, A. L. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781316091586.021 · Cited by 1
Vaccines Against Non-Infectious, Non-Cancer Novel Targets
Garside, D. A., Acevedo, R., Alsaadi, M., Nimmo, N., Gebril, A., Lamprou, D. A., Mullen, A. B., & Ferro, V. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-416603-5.00010-9 · Cited by 1
Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Mouse Models
Ittner, L. M., Lee, W. S., Stefanoska, K., Asih, P. R., & Ke, Y. D. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_10 · Cited by 1
Investigación y terapias en la enfermedad de Alzheimer basadas en beta amiloide y tau
López-Camacho, P. Y., Guzmán-Hernández, R. N.-H., Gonzalez, V. H. H., Muñoz, J. E. D., García‐Sierra, F., & Basurto‐Islas, G. (2017) · Archivos de Neurociencias · doi:10.31157/an.v22i2.154 · Cited by 1
Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Mouse Models
van Eersel, J., Delerue, F., Ittner, L. M., & Ke, Y. D. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6380-0_8
Plant-based vaccines for Alzheimer's disease: an
Dania, O., & Moreno‐Fierros, L. (2014)
Tau Pathology: A Selected View on the Current Status
Gozes, I. (2012) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-94-007-5866-7_5
Active immunotherapy options for Alzheimer's
Winblad, B. G., Graf, A., Riviere, M., Andreasen, N., & Ryan, J. M. (2014)
Treatment
Dickerson, B. C. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781316091586.019
Active and Passive Immunotherapy Against Tau: Effects and Potential Mechanisms
Yanamandra, K., Diamond, M. I., & Holtzman, D. M. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_9
Tau-Directed Immunotherapy for Alzheimer's Disease
Schroeder, S. K. (2017) · Digital Commons - University of South Florida (University of South Florida)
Nitrate Chimeras: A New Class of Disease Modifying Agents for the Treatment of Alzheimer's Disease
VandeVrede, L. A. (2014) · Figshare
INVESTIGATION INTO THE FUNCTIONAL ROLES OF TAU AND ALPHA-SYNUCLEIN IN NEURODEGENERATIVE DISEASE
Morris, M. (2014)
Analysis of Immunotherapy Methods for Alzheimer's Disease
Huang, J. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.au23579
Tau‐targeting active immunotherapy slows progression and reduces pathology in mouse models of tauopathy
Brown, C. M., Brooks, J. K., Kelly, L., Vroom, M. M., Longo, M., Dodart, J., Carare, R. O., & Boyd, J. D. (2025) · Brain Pathology · doi:10.1111/bpa.70056
Validation préclinique de l'efficacité de l'ANAVEX2-73 dans des modèles transgénique et non transgénique de la maladie d'Alzheimer
Lahmy, V. (2014) · theses.fr (ABES) · doi:10.70675/23744d67zb26bz4a32zadbfz3931ecca70f5
Prévention du phénomène de nucléation et de la propagation des tauopathies par immunothérapie passive utilisant un anticorps ciblant une région centrale de la protéine tau
Albert, M. (2018) · theses.fr (ABES) · doi:10.70675/7563255bz78adz4fe1zb0e6zc298f8457886
Rôle des cellules T CD4+ dans la modulation des réponses microgliales au cours de la maladie d’Alzheimer : potentialités thérapeutiques
Ahmed, D. A. (2014) · theses.fr (ABES) · doi:10.70675/9f4f1101zd66fz4e13zadffzc6a36a19d81c
BindingDB Entry 50042999: Progress and developments in tau aggregation inhibitors for Alzheimer disease.
BindingDB (2014) · UC San Diego · doi:10.7270/q2ht2qqd

Authors: Boimel, M., Grigoriadis, N., Lourbopoulos, A., Haber, E., Abramsky, O., & Rosenmann, H.
Affiliations: Hebrew University of Jerusalem (IL)
AHEPA University Hospital (GR)
Corresponding author: Rosenmann, Hanna
ORCID: Grigoriadis, Nikolaos
Venue: Experimental Neurology
Publisher: Elsevier BV
Published: 2010-08
Volume: 224
Issue: 2
Pages: 472-485
ISSN: 0014-4886 (ISSN-L)
DOI: 10.1016/j.expneurol.2010.05.010
OpenAlex: W2091935655
Cited by: 174
References: 41
Citations by year: 2026: 1 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 4 · 2020: 8 · 2019: 10 · 2018: 11 · 2017: 15 · 2016: 8 · 2015: 19 · 2014: 32 · 2013: 23 · 2012: 15
FWCI: 12.56
Type: journal article
Language: en
Update notices: erratum (2013-09-01)
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Experimental Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: phosphorylated tau, neurofibrillary tangles, tau immunotherapy, Alzheimer's disease, tauopathy, encephalitogenicity, microglia, lysosomal proteases, anti-tau antibodies, pertussis toxin, complete Freund's adjuvant, neuroinflammation
MeSH terms: Animals, Antibodies, Astrocytes, Brain, Cathepsin D, Encephalitis, Female, Immunization, Lysosomes, Mice, Transgenic, Neurons, Peptide Fragments, Peptide Hydrolases, Phosphoproteins, Vaccines, Synthetic, Neurofibrillary Tangles, tau Proteins, Microglia, Tauopathies, Mice, Cathepsin L

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks